Evaluation of serum tumor markers in assessing the efficacy of TP (Paclitaxel plus Carboplatin) chemotherapy combined with trastuzumab and pertuzumab dual target therapy in HER2-positive breast cancer.

This study aims to evaluate the efficacy of TP (paclitaxel plus carboplatin) chemotherapy combined with trastuzumab and pertuzumab dual-target therapy for HER2-positive breast cancer using serum tumor markers. A total of 96 patients with HER2-positive breast cancer treated at our hospital from January 2021 to January 2023 were selected and randomly divided into a control group and a study group, with 48 cases in each group. The efficacy and safety of the treatments were compared between the two groups. Serum levels of CEA, CA125, and CA153 were measured before and after treatment. After treatment, the overall response rate and disease control rate in the study group were significantly higher than those in the control group (P < 0.05). There were no significant differences in serum levels of CEA, CA125, and CA153 between the two groups before treatment (P > 0.05). However, after treatment, the serum levels of CEA, CA125, and CA153 in the study group were significantly lower than those in the control group (P < 0.05). ROC curve analysis showed that the combined prediction of CEA, CA125, and CA153 had higher AUC, sensitivity, and specificity compared to individual markers. There were no significant differences between the two groups in terms of liver function abnormalities, hemoglobin reduction, platelet reduction, cardiotoxicity, gastrointestinal symptoms, and joint muscle pain (P > 0.05). Evaluating the efficacy of TP (paclitaxel plus carboplatin) chemotherapy combined with trastuzumab and pertuzumab dual-target therapy for HER2-positive breast cancer using serum tumor markers has significant clinical value.